当前位置: 首页 > 详情页

Status of hyperhomocysteinemia in China: results from the China Stroke High-risk Population Screening Program, 2018

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C

机构: [1]Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China [2]TheGeneral Office of Stroke Prevention Project Committee, National Health Commission of the People’s Republic of China, Beijing 100053,China [3]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China [4]Department ofNeurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
出处:
ISSN:

关键词: homocysteine hyperhomocysteinemia H-type hypertension Chinese

摘要:
A nationwide survey was conducted from October 2018 to September 2019 to assess the prevalence of hyperhomocysteinemia (Hhcy) and its influencing factors in China. A standardized questionnaire was used to collect information. Hhcy was defined as the level of serum homocysteine (HCY) > 15.0 mu mol/L. The H-type hypertension (HHYP) was defined as hypertension with an elevated serum HCY 15.0 mu mol/L). Finally, 110 551 residents > 40 years of age from 31 provinces in the mainland of China were included. Overall, the median serum HCY level was 10.9 mu mol/L (interquartile range 7.9-15.1). A total of 28 633 participants (25.9%) were defined as Hhcy. The Hhcy prevalence ranged from 7.9% in Shanghai to 56.8% in Tianjin. The data showed that serum HCY levels were associated with age, male gender, cigarette smoking, hypertension, diabetes, ethnicity, endurance in exercise (inverse), and fruit and vegetable intake (inverse). In addition, 15 486 participants were defined as HHYP, and the rate was 14.0%. HHYP was an independent predictor of stroke with an adjusted odds ratio of 1.752 (95% CI 1.338-2.105). The geographical distribution pattern of the Hhcy epidemic reflects dynamic differences, and national strategies should be carried out to further improve the care of patients with Hhcy across China.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 3 区 医学
小类 | 3 区 医学:研究与实验 3 区 肿瘤学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:内科 2 区 医学:研究与实验 2 区 肿瘤学
JCR分区:
出版当年[2019]版:
Q2 ONCOLOGY Q2 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China [2]TheGeneral Office of Stroke Prevention Project Committee, National Health Commission of the People’s Republic of China, Beijing 100053,China [3]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17069 今日访问量:2 总访问量:918 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院